Project Grant P01CA295524
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$2.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute awarded a $627,474 Project Grant under its Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Dana-Farber Cancer Institute in Boston, Massachusetts. The grant will fund a 5-year research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative...
This federal Project Grant award of $1,082,472 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to determine the molecular mechanisms underlying the transition of prostate cancer from a luminal to a neuroendocrine phenotype. The primary objectives are to investigate how the transcription factors FOXA2 and NKX2-1 interact to drive this "luminal-to-neuroendocrine transdifferentiation" process, and to evaluate the role...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $1,574,670 Project Grant from the Defense Health Agency to support the "TUMOR IMMUNOTHERAPY BY GENE-CIRCUIT ENGINEERED RESPONSE (TIGER) GOT NEUROENDOCRINE PROSTATE CANCER" research effort. The grant was awarded on March 15, 2023 under the Military Medical Research and Development program (CFDA 12.420), with work to be completed by March 14, 2026 in Boston, MA.
The Military Medical Research and Development program aims to...
This $392,410 National Cancer Institute (NCI) Project Grant award, issued under the Cancer Research Manpower program (CFDA 93.398), supports research at Weill Medical College of Cornell University to investigate the drivers of tumor heterogeneity and the progression to neuroendocrine prostate cancer (NEPC). The 3-year project will use novel genetically-engineered mouse models and organoid-based platforms to study the role of a previously undescribed tumor subpopulation in the transition from...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...
The Federal Project Grant award in the amount of $2,136,000.00 was provided by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Dana-Farber Cancer Institute, Inc. (DFCI) to fund research on "Reversibility and Therapeutic Targeting of Treatment-Emergent Neuroendocrine Prostate Cancer." The award period is from May 1, 2025 to April 30, 2028. The grant supports DFCI's cancer research efforts, which involve conducting basic, clinical, and...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Icahn School of Medicine at Mount Sinai to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancer (SCLC). The project aims to: 1) determine how cell-of-origin and the transcription factor NKX2-1 impact the evolution and maintenance of epigenomic SCLC states, 2) determine the mechanisms for pulmonary to neuronal...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
The National Cancer Institute awarded a $1,396,100 Project Grant (CFDA 93.396 - Cancer Biology Research) to President and Fellows of Harvard College, doing business as Harvard Medical School, to conduct research on defining the evolutionary history and genetic characteristics of peritoneal metastases in colorectal cancer patients. The key goals are to map the seeding routes of peritoneal metastases, determine the genetic traits of cancer cells that successfully colonize the peritoneum, and...